Cellectis S.A. (NASDAQ: CLLS) is experiencing an extraordinary surge in its stock price, soaring by an impressive 192.01% to reach $2.8150. That is also accompanied
Alterity Therapeutics Limited (ATHE) stock plunged -10.31% to $2.0 in the pre-market trading after the company announced the approval of a US patent for the
Cellectis (Nasdaq: CLLS), a biopharmaceutical firm, today confirmed the appointment of Kyung Nam-Wortman as Chief Human Resources Officer and Executive Vice President of Cellectis. Also
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.